One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold nearly 3.6 million shares of Syros Pharmaceuticals Inc. (NASDAQ: SYRS) on Wednesday, as the share price of this fund traded up nearly 2% in the day’s session. The fund’s share price has greatly improved over the past year.
ARK Innovation ETF (NYSEARCA: ARKK) sold 3,574,908 shares of Syros Pharma. At Wednesday’s closing price, this would have valued this sale at roughly $20.0 million. This is only a small fraction of the total holdings. ARKK is up 81% over the past 52 weeks.
Here is a quick look at all the other sales that took place across all ARK ETFs:
|ARKF||6060HK||ZHONGAN ONLINE P&C INSURANCE CO LTD||677,300|
|ARKF||GWRE||GUIDEWIRE SOFTWARE INC||246|
|ARKG||GH||GUARDANT HEALTH INC||10,800|
|ARKG||PSTI||PLURISTEM THERAPEUTICS INC||50,671|
|ARKG||TAK||TAKEDA PHARMACEUTICAL CO LTD||78,202|
|ARKK||SYRS||SYROS PHARMACEUTICALS INC||3,574,908|
|ARKK||ONVO||ORGANOVO HOLDINGS INC||8,989|
|ARKQ||GLEO||GALILEO ACQUISITION CORP||22,423|
|ARKX||RAVN||RAVEN INDUSTRIES INC||9,215|
|ARKX||WKHS||WORKHORSE GROUP INC||6|
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St., owner of 247wallst.com.